何氏眼科(301103)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

301103 何氏眼科

已收盘 04-03 15:00:00

{"stockData":{"symbol":"301103","market":"SZ","secType":"STK","nameCN":"何氏眼科","latestPrice":19.05,"timestamp":1775199783000,"preClose":19.75,"halted":0,"volume":1950130,"delay":0,"changeRate":-0.0354,"floatShares":122000000,"shares":158000000,"eps":0.0673,"marketStatus":"已收盘","change":-0.7,"latestTime":"04-03 15:00:00","open":19.75,"high":19.83,"low":18.93,"amount":37481000,"amplitude":0.0456,"askPrice":19.06,"askSize":11,"bidPrice":19.05,"bidSize":65,"shortable":0,"etf":0,"ttmEps":0.0673,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1775525400000},"marketStatusCode":5,"adr":0,"adjPreClose":19.75,"symbolType":"stock","openAndCloseTimeList":[[1775179800000,1775187000000],[1775192400000,1775199600000]],"highLimit":21.73,"lowLimit":17.78,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":158026471,"isCdr":false,"pbRate":1.63,"roa":"--","peRate":283.060921,"roe":"2.87%","epsLYR":-0.1734,"committee":0.629213,"marketValue":3010000000,"turnoverRate":0.016,"status":1,"floatMarketCap":2317000000},"requestUrl":"/m/hq/s/301103","defaultTab":"news","newsList":[{"id":"2622707212","title":"何氏眼科（301103）披露2026年度日常关联交易预计公告，3月25日股价上涨0.42%","url":"https://stock-news.laohu8.com/highlight/detail?id=2622707212","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622707212?lang=zh_cn&edition=full","pubTime":"2026-03-25 22:31","pubTimestamp":1774449063,"startTime":"0","endTime":"0","summary":"截至2026年3月25日收盘，何氏眼科报收于19.28元，较前一交易日上涨0.42%，最新总市值为30.47亿元。公司于近日披露《关于2026年度日常关联交易预计的公告》。公告显示，辽宁何氏眼科医院集团股份有限公司预计2026年度日常关联交易总额约为3,919.30万元，主要包括向关联人采购商品、接受劳务、租赁房屋以及向关联人提供劳务、技术服务和出租服务器等。关联交易遵循市场定价原则，交易价格公允。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032500044353.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0236","301103"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622076611","title":"何氏眼科：公司将审慎研究论证股份回购注销事宜","url":"https://stock-news.laohu8.com/highlight/detail?id=2622076611","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622076611?lang=zh_cn&edition=full","pubTime":"2026-03-25 20:48","pubTimestamp":1774442910,"startTime":"0","endTime":"0","summary":"证券之星消息，何氏眼科03月24日在投资者关系平台上答复投资者关心的问题。关于股份回购注销事宜，公司将结合财务状况、资金安排、发展规划与市场情况审慎研究论证。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032500041621.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0236","301103"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621068596","title":"何氏眼科（301103）披露董事长代行董事会秘书职责公告，3月24日股价上涨3.5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2621068596","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621068596?lang=zh_cn&edition=full","pubTime":"2026-03-24 17:24","pubTimestamp":1774344299,"startTime":"0","endTime":"0","summary":"截至2026年3月24日收盘，何氏眼科报收于19.2元，较前一交易日上涨3.5%，最新总市值为30.34亿元。该股当日开盘18.78元，最高19.25元，最低18.32元，成交额达4815.8万元，换手率为1.62%。公告显示，公司原董事会秘书周晋峰因个人原因辞职，此前曾指定总经理何星儒代行董事会秘书职责；截至公告日，代行期限已满三个月。根据相关规定，董事长何伟将自该日起代行董事会秘书职责，直至聘任新任董事会秘书。公告同时列明了何伟代行期间的公司联系方式。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032400029390.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301103","BK0236"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621105273","title":"何氏眼科最新公告：董事长何伟代行董事会秘书职责","url":"https://stock-news.laohu8.com/highlight/detail?id=2621105273","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621105273?lang=zh_cn&edition=full","pubTime":"2026-03-24 16:24","pubTimestamp":1774340662,"startTime":"0","endTime":"0","summary":"何氏眼科(301103.SZ)公告称，因原董事会秘书周晋峰辞职，公司总经理何星儒此前代行董事会秘书职责已满三个月。根据深交所相关规定，自本公告披露日起，由董事长何伟代行董事会秘书职责，并将在六个月内完成新任董事会秘书的聘任工作。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032400026895.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0236","301103"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2608762568","title":"何氏眼科：战略性投入比短期回购更能为公司创造可持续价值","url":"https://stock-news.laohu8.com/highlight/detail?id=2608762568","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608762568?lang=zh_cn&edition=full","pubTime":"2026-02-03 20:52","pubTimestamp":1770123151,"startTime":"0","endTime":"0","summary":"证券之星消息，何氏眼科02月02日在投资者关系平台上答复投资者关心的问题。我们认为，战略性投入比短期回购更能为公司创造可持续价值。未来若触发回购条件或出现更优时机，公司将依法依规履行决策程序并及时披露。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020300040786.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301103","BK0236"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2606200343","title":"何氏眼科：预计2025年全年归属净利润盈利2400万元至3600万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2606200343","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606200343?lang=zh_cn&edition=full","pubTime":"2026-01-27 18:03","pubTimestamp":1769508224,"startTime":"0","endTime":"0","summary":"证券之星消息，何氏眼科发布业绩预告，预计2025年全年归属净利润盈利2400万元至3600万元。何氏眼科2025年三季报显示，前三季度公司主营收入8.55亿元，同比下降1.11%；归母净利润5439.53万元，同比上升232.18%；扣非净利润4242.87万元，同比上升186.89%；其中2025年第三季度，公司单季度主营收入2.95亿元，同比上升5.37%；单季度归母净利润1007.07万元，同比上升230.99%；单季度扣非净利润518.71万元，同比上升154.22%；负债率15.26%，投资收益973.97万元，财务费用87.07万元，毛利率41.83%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012700031171.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301103"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2606228973","title":"股市必读：何氏眼科（301103）1月26日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2606228973","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606228973?lang=zh_cn&edition=full","pubTime":"2026-01-27 02:40","pubTimestamp":1769452821,"startTime":"0","endTime":"0","summary":"截至2026年1月26日收盘，何氏眼科报收于21.54元，下跌0.6%，换手率1.66%，成交量2.62万手，成交额5624.31万元。董秘最新回复投资者： 截至2025年9月30日，公司账上货币资金和交易性金融资产分别为3.65亿元和10.07亿元，且没有任何有息负债！公司将更聚焦于智慧医疗技术的应用落地，而非技术研发本身。交易信息汇总资金流向1月26日主力资金净流出231.82万元；游资资金净流出843.96万元；散户资金净流入1075.79万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012700001983.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0236","301103"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2606290689","title":"何氏眼科：公司将更聚焦于智慧医疗技术的应用落地","url":"https://stock-news.laohu8.com/highlight/detail?id=2606290689","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606290689?lang=zh_cn&edition=full","pubTime":"2026-01-26 16:06","pubTimestamp":1769414771,"startTime":"0","endTime":"0","summary":"证券之星消息，何氏眼科01月26日在投资者关系平台上答复投资者关心的问题。公司将更聚焦于智慧医疗技术的应用落地，而非技术研发本身。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012600015647.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301103","BK0236"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2605172490","title":"何氏眼科：2026年公司营业收入不低于12亿元；或2026年公司净利润不低于4,000万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2605172490","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605172490?lang=zh_cn&edition=full","pubTime":"2026-01-21 16:57","pubTimestamp":1768985843,"startTime":"0","endTime":"0","summary":"证券之星消息，何氏眼科01月21日在投资者关系平台上答复投资者关心的问题。何氏眼科回复：尊敬的投资者您好，根据公司已披露的《2025年限制性股票激励计划（草案）》，公司设定了2026年业绩考核目标：2026年公司营业收入不低于12亿元；或2026年公司净利润不低于4,000万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012100027396.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301103"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2604113942","title":"何氏眼科：股权激励股票来源为二级市场回购或定向发行","url":"https://stock-news.laohu8.com/highlight/detail?id=2604113942","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2604113942?lang=zh_cn&edition=full","pubTime":"2026-01-20 20:52","pubTimestamp":1768913531,"startTime":"0","endTime":"0","summary":"证券之星消息，何氏眼科(301103)01月19日在投资者关系平台上答复投资者关心的问题。投资者提问：贵公司提出的股权激励方案，为何仍有部分股票是通过直接发行股票变相扩大了总股本数，而不是通过二级市场回购呢？何氏眼科回复：尊敬的投资者您好，公司 2025 年限制性股票激励计划的股票来源为公司自二级市场回购和/或向激励对象定向发行的公司A股普通股股票，该安排严格遵循《上市公司股权激励管理办法》等相关法律法规要求。谢谢！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012000037361.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301103","BK0236"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2604972538","title":"股市必读：何氏眼科（301103）1月16日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2604972538","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2604972538?lang=zh_cn&edition=full","pubTime":"2026-01-19 04:13","pubTimestamp":1768767188,"startTime":"0","endTime":"0","summary":"截至2026年1月16日收盘，何氏眼科报收于21.26元，下跌0.47%，换手率1.26%，成交量1.99万手，成交额4214.86万元。公司公告汇总关于持股5%以上股东减持股份预披露公告辽宁何氏眼科医院集团股份有限公司于近日收到持股5%以上股东先进制造产业投资基金出具的《关于股份减持计划的告知函》。本次减持不会导致公司控制权变更，不影响公司治理结构和持续经营。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011900001581.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301103","BK0236"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2604920972","title":"何氏眼科最新公告：先进制造基金拟减持公司不超1.97%股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2604920972","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2604920972?lang=zh_cn&edition=full","pubTime":"2026-01-18 16:40","pubTimestamp":1768725606,"startTime":"0","endTime":"0","summary":"何氏眼科(301103.SZ)公告称，公司持股6.54%的股东先进制造产业投资基金（有限合伙）（简称“先进制造基金”）计划通过集中竞价和大宗交易方式，减持公司股份合计不超过310.61万股，占公司总股本的1.97%。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011800005154.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301103","399260","BK0236"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2603963778","title":"何氏眼科：构建“互联网+医疗健康”全生命周期眼健康管理平台","url":"https://stock-news.laohu8.com/highlight/detail?id=2603963778","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603963778?lang=zh_cn&edition=full","pubTime":"2026-01-16 16:00","pubTimestamp":1768550448,"startTime":"0","endTime":"0","summary":"此外，何氏眼科“光明小屋”以智能眼科设备为入口，结合线上线下诊疗体系，通过智能诊断技术筛查眼部疾病及相关慢性病，打造数字技术赋能的基层眼健康管理场景。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011600020920.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["160636","301103","159792","159760","BK0236"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2603963765","title":"何氏眼科：招华基金投资契合公司长期战略","url":"https://stock-news.laohu8.com/highlight/detail?id=2603963765","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603963765?lang=zh_cn&edition=full","pubTime":"2026-01-16 16:00","pubTimestamp":1768550447,"startTime":"0","endTime":"0","summary":"证券之星消息，何氏眼科01月16日在投资者关系平台上答复投资者关心的问题。目前公司与招华基金保持紧密沟通对接，基金正积极推进项目寻找与筹备立项工作。敬请投资者理性看待产业基金投资的周期性特点，注意投资风险。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011600020916.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301103","BK0236"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2603031936","title":"何氏眼科（301103）披露2026年第一次临时股东会决议公告，1月15日股价下跌0.47%","url":"https://stock-news.laohu8.com/highlight/detail?id=2603031936","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603031936?lang=zh_cn&edition=full","pubTime":"2026-01-15 17:40","pubTimestamp":1768470032,"startTime":"0","endTime":"0","summary":"截至2026年1月15日收盘，何氏眼科报收于21.36元，较前一交易日下跌0.47%，最新总市值为33.75亿元。该股当日开盘21.4元，最高21.63元，最低21.18元，成交额达4068.12万元，换手率为1.2%。近日，辽宁何氏眼科医院集团股份有限公司发布2026年第一次临时股东会决议公告。出席会议股东共84人，代表股份占公司有表决权股份总数的56.4996%。北京市中伦律师事务所对本次会议出具了法律意见书，认为会议召集、召开程序合法合规，表决结果有效。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011500029263.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301103","BK0236"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2602517929","title":"何氏眼科：坚持聚焦主业稳健经营","url":"https://stock-news.laohu8.com/highlight/detail?id=2602517929","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602517929?lang=zh_cn&edition=full","pubTime":"2026-01-12 20:48","pubTimestamp":1768222100,"startTime":"0","endTime":"0","summary":"证券之星消息，何氏眼科01月12日在投资者关系平台上答复投资者关心的问题。公司坚信，长期稳定的市值源于扎实的经营业绩与清晰的价值逻辑。未来，公司坚持长期可持续发展战略、透明的信息披露与有效的投资者沟通，稳步推进资本市场品牌建设，努力为投资者创造长期价值。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011200034403.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0236","301103"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2602179115","title":"何氏眼科：审慎推进并购重组","url":"https://stock-news.laohu8.com/highlight/detail?id=2602179115","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602179115?lang=zh_cn&edition=full","pubTime":"2026-01-12 20:48","pubTimestamp":1768222099,"startTime":"0","endTime":"0","summary":"证券之星消息，何氏眼科(301103)01月12日在投资者关系平台上答复投资者关心的问题。投资者提问：公司收购并购能不能既考虑盈利性，又考虑题材概念性？何氏眼科回复：尊敬的投资者您好， 在并购战略层面，公司遵循业务协同、战略协同、风险可控的原则。未来，公司将结合行业发展趋势、自身经营需求及标的资产质量，审慎推进并购重组。若后续有相关计划达到信息披露标准，将严格按照法律法规要求及时履行披露义务，切实维护全体股东利益。敬请谨慎决策、注意投资风险。感谢您的关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011200034401.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0236","161123","301103"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2602437508","title":"何氏眼科：坚定看好中国眼科行业长期发展前景","url":"https://stock-news.laohu8.com/highlight/detail?id=2602437508","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602437508?lang=zh_cn&edition=full","pubTime":"2026-01-09 20:51","pubTimestamp":1767963107,"startTime":"0","endTime":"0","summary":"证券之星消息，何氏眼科01月08日在投资者关系平台上答复投资者关心的问题。上述事项对公司当前主营业务开展或业绩未造成重大影响，敬请谨慎决策、注意投资风险。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010900038193.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301103","BK0236"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2601364955","title":"何氏眼科：将根据资金安排考量回购计划","url":"https://stock-news.laohu8.com/highlight/detail?id=2601364955","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601364955?lang=zh_cn&edition=full","pubTime":"2026-01-08 20:51","pubTimestamp":1767876678,"startTime":"0","endTime":"0","summary":"证券之星消息，何氏眼科(301103)01月07日在投资者关系平台上答复投资者关心的问题。投资者提问：贵公司之前在股价25左右曾经大幅回购股票，为何目前在20附近却不果断出手回购呢？目前股价处于低位，建议公司管理层果断出手维护市场稳定！何氏眼科回复：尊敬的投资者您好，对于您提及的相关举措，公司管理层将根据公司资金安排并结合实际经营情况及未来发展需求等多种因素考量，未来如有回购相关计划，将严格按照法律法规及交易所规则，履行决策程序并及时披露相关信息。感谢您的建议。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010800036915.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0236","301103"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2601878496","title":"何氏眼科：沈阳爱络博智能科技从事眼科器械研发","url":"https://stock-news.laohu8.com/highlight/detail?id=2601878496","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601878496?lang=zh_cn&edition=full","pubTime":"2026-01-07 16:18","pubTimestamp":1767773907,"startTime":"0","endTime":"0","summary":"证券之星消息，何氏眼科(301103)01月07日在投资者关系平台上答复投资者关心的问题。投资者提问：贵公司的关联公司沈阳爱络博智能科技有限公司在脑机接口领域有哪些布局？何氏眼科回复：尊敬的投资者您好，沈阳爱络博智能科技有限公司为公司实际控制人控制的关联企业，并非公司直接参股公司。其主要从事眼科相关医疗器械、智能软硬件系统的研发、生产与销售。谢谢！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010700021359.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0236","301103"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1775254419235,"stockEarnings":[{"period":"1week","weight":-0.0231},{"period":"1month","weight":-0.0698},{"period":"3month","weight":-0.0291},{"period":"6month","weight":-0.081},{"period":"1year","weight":-0.0632},{"period":"ytd","weight":-0.0291}],"compareEarnings":[{"period":"1week","weight":-0.0086},{"period":"1month","weight":-0.0496},{"period":"3month","weight":-0.0224},{"period":"6month","weight":-0.0007},{"period":"1year","weight":0.161},{"period":"ytd","weight":-0.0224}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"辽宁何氏眼科医院集团股份有限公司","boardCode":"AI0083","boardName":"卫生","stockholders":"9888人(较上一季度减少8.55%)","perCapita":"12301股","listingDate":"2022-03-22","address":"辽宁省沈阳市浑南区天赐街5-1号(607)","registeredCapital":"15802万元","survey":"　　辽宁何氏眼科医院集团股份有限公司的主营业务是向眼病患者提供眼科专科诊疗服务和视光服务。公司的主要产品是眼科专科诊疗服务和视光服务。","listedPrice":42.5},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.39.0","shortVersion":"4.39.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"何氏眼科(301103)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供何氏眼科(301103)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"何氏眼科,301103,何氏眼科股票,何氏眼科股票老虎,何氏眼科股票老虎国际,何氏眼科行情,何氏眼科股票行情,何氏眼科股价,何氏眼科股市,何氏眼科股票价格,何氏眼科股票交易,何氏眼科股票购买,何氏眼科股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"何氏眼科(301103)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供何氏眼科(301103)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}